Description
Ibrance (Palbociclib) 75mg Online
Ibrance (Palbocent) Palbociclib capsules are a chemotherapy drug indicated for the treatment of certain types of breast cancer. It contains the active ingredient palbociclib which can stop the growth of certain types of hormone receptor-positive tumors. Ibrance is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or fulvestrant in patients with disease progression following endocrine therapy.
Ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
According to the FDA, the majority of male breast tumors express hormone receptors. Males are more likely to be diagnosed at an older age with a more advanced stage of the disease.
Ibrance was first approved in 2015. Ibrance is a kinase inhibitor approved in combination with an aromatase inhibitor as the first hormonal-based therapy in women who have gone through menopause and in men, or with fulvestrant in patients whose disease progressed after hormonal therapy. The drug is approved in more than 90 countries.
Pfizer points out that the use of real-world data (RWD) in clinical trials is playing an increasingly important role. Due to the rarity of breast cancer in males, fewer clinical trials are conducted that include men resulting in fewer approved treatment options.
The approval was built on data from electronic health records and postmarketing data citing real-world use of Ibrance in male patients that came from three databases: IQVIA Insurance database, Flatiron Health Breast Cancer database, and the Pfizer global safety database.
